OCT1 Variants rs628031 and rs622342 Modulate Metformin Clearance and Gluconeogenesis in Youth-Onset T2D
Background
Variability in treatment response to metformin in youth-onset type 2 diabetes (Y-T2D), particularly among African Americans, is not fully explained by behavioral or phenotypic characteristics. Current standard-of-care often falls short due to this heterogeneity, leading to suboptimal glycemic control. This study hypothesized that biological factors, specifically genetic variations in the organic cation transporter 1 (OCT1), a key metformin transporter, influence metformin pharmacokinetics and hepatic glucose production, addressing a critical gap in understanding personalized Y-T2D management.
Study Design
Researchers employed a candidate-gene approach in 30 Y-T2D patients to evaluate associations between pharmacogenetic variants and fasting glucose and gluconeogenesis. In a subset, 19 Y-T2D patients were randomized for 3 months to either metformin (n=11) or metformin + liraglutide (n=8). A metformin population pharmacokinetic model was constructed, and genetic variant associations were evaluated. The study used pharmacokinetic modeling and assessed fractional gluconeogenesis and fasting glucose as primary endpoints.
Results
A one-compartment first-order absorption and elimination pharmacokinetic model provided the optimal fit for metformin. Metformin pharmacokinetic parameters were similar across treatment groups and not directly related to glycemia. However, the rs628031_OCT1 A allele was significantly associated with greater metformin clearance. The study also found a strong link between another OCT1 variant and glucose metabolism:
The rs622342_OCT1 C allele was associated with lower post-treatment fractional gluconeogenesis (β [95% CI] = -8.8 [-14.13, -3.47] %, Adjusted R2 = 0.56, P = 0.003). Furthermore, the rs7903146_TCF7L2 T allele was associated with greater reductions in fasting glucose among those treated with metformin + liraglutide (β = -1.32 [-2.42, -0.22] mmol/L, Adjusted R2 = 0.8, P <0.002). Despite these genetic influences, baseline glucose and gluconeogenesis (P <0.0001) remained the strongest predictors of post-treatment glycemia.
Key Findings
- The rs628031_OCT1 A allele was associated with greater metformin clearance.
- The rs622342_OCT1 C allele correlated with -8.8% lower post-treatment fractional gluconeogenesis (P = 0.003).
- The rs7903146_TCF7L2 T allele linked to -1.32 mmol/L greater fasting glucose reduction with metformin + liraglutide (P <0.002).
- Baseline glucose and gluconeogenesis were the strongest predictors of post-treatment glycemia (P <0.0001).
Why It Matters
This research highlights the potential for personalized medicine in youth-onset T2D, suggesting that genetic testing for OCT1 variants could guide metformin dosing or treatment selection. Identifying patients with specific OCT1 alleles, such as rs628031, could help predict metformin clearance rates, potentially informing higher or lower initial doses to optimize efficacy and minimize side effects. For those on metformin + liraglutide, TCF7L2 variant rs7903146 might identify individuals who will experience greater fasting glucose reductions, allowing for more targeted combination therapy. This moves beyond a one-size-fits-all approach, paving the way for genetically informed treatment protocols.
metformin
liraglutide
type-2-diabetes
youth-onset-t2d
oct1
tcf7l2